PharmaResources (Shanghai) Co. Ltd. A - Asset Resilience Ratio
PharmaResources (Shanghai) Co. Ltd. A (301230) has an Asset Resilience Ratio of 18.09% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read PharmaResources (Shanghai) Co. Ltd. A (301230) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2024)
This chart shows how PharmaResources (Shanghai) Co. Ltd. A's Asset Resilience Ratio has changed over time. See 301230 net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down PharmaResources (Shanghai) Co. Ltd. A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 301230 market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥245.34 Million | 18.09% |
| Total Liquid Assets | CN¥245.34 Million | 18.09% |
Asset Resilience Insights
- Good Liquidity Position: PharmaResources (Shanghai) Co. Ltd. A maintains a healthy 18.09% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
PharmaResources (Shanghai) Co. Ltd. A Industry Peers by Asset Resilience Ratio
Compare PharmaResources (Shanghai) Co. Ltd. A's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for PharmaResources (Shanghai) Co. Ltd. A (2021–2024)
The table below shows the annual Asset Resilience Ratio data for PharmaResources (Shanghai) Co. Ltd. A.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 19.13% | CN¥251.77 Million ≈ $36.84 Million |
CN¥1.32 Billion ≈ $192.63 Million |
-3.79pp |
| 2023-12-31 | 22.92% | CN¥340.79 Million ≈ $49.87 Million |
CN¥1.49 Billion ≈ $217.62 Million |
+22.10pp |
| 2022-12-31 | 0.82% | CN¥10.65 Million ≈ $1.56 Million |
CN¥1.30 Billion ≈ $190.42 Million |
+0.75pp |
| 2021-12-31 | 0.07% | CN¥397.68K ≈ $58.19K |
CN¥557.81 Million ≈ $81.62 Million |
-- |
About PharmaResources (Shanghai) Co. Ltd. A
PharmaResources (Shanghai) Co., Ltd. engages in new drug research, development, and commercial production in China. It offers small molecule drug CRO, CDMO, and CMO. The company also involved in drug discovery, research, and development of pharmaceutical processes; and customized and commercial production of APIs, and key intermediates. It serves global pharmaceutical and biotechnology companies.… Read more